Skip to main navigation
  • About
    • Our Vision
    • Our Approach
    • Our Team
  • Pipeline
    • DARE-BV1
    • OVAPRENE®
    • Sildenafil Cream, 3.6%
  • Partners
  • Consumers
  • Investors
    • Overview
    • Press Releases
    • Presentation, Events & Webcasts
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Analyst Coverage
    • Financial Information
      • Financials Overview
      • SEC Filings
      • Annual Reports & Proxies
      • Quarterly Results
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
    • Contact
  • Careers
  • Contact Us
    Dare Biosciences
    • Investors
    • Press releases
    • Presentations, Events & Webcasts
    • Stock information
    • Financial Information
    • Corporate governance
    • Contact

    Press Release

    Daré Bioscience to Participate in Three February Conferences

    02-01-2023 at 8:00 AM EST
    PDF Version

    SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following February conferences:

    2023 BIO CEO & Investor Conference
    February 6-9, 2023, New York Marriott Marquis, New York, NY
    Company presentation: Tuesday, February 7th at 3:00 p.m. EST
    Ms. Johnson will be available for one-on-one meetings.

    SVB Securities Global Biopharma Conference
    February 13-16, 2023, Virtual
    Members of the company’s management team will be available for one-on-one meetings.

    3rd Annual Women’s Health Innovation Series: Reproductive Health Innovation Summit
    February 15-16, 2023, Boston Park Plaza, Boston, MA

        Panel Presentation: Contraception: Traversing the Lesser-Known Male Space
      Thursday, February 16th at 3:30 p.m. EST
      Moderator: Heather Vahdat, Executive Director, Male Contraceptive Initiative
      Kevin Eisenfrats, Co-Founder & CEO, Contraline
      Stasia Obremskey, Managing Director, RH Capital
      Sabrina Martucci Johnson, President & CEO, Daré Bioscience
      Akash Bakshi, CEO, YourChoice Therapeutics

    About Daré Bioscience

    Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, vaginal, and reproductive, menopause, and sexual health.

    Daré’s first FDA-approved product, XACIATOTM (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

    Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

    Contacts:

    Investors on behalf of Daré Bioscience, Inc.:
    Lee Roth
    Burns McClellan
    lroth@burnsmc.com
    212.213.0006

    OR

    Media on behalf of Daré Bioscience, Inc.:
    Jake Robison
    Evoke Canale
    jake.robison@evokegroup.com
    619.849.5383

    Source: Daré Bioscience, Inc.


    Primary Logo

    Source: Daré Bioscience, Inc.

    • Request email alerts |
    • Print this page |
    • Search investor site |

    © 2023 by Daré Bioscience | Daré Bioscience® is a registered trademark of Daré Bioscience, Inc.

    Privacy Policy | Terms of Service | COI Policy |

    Scroll to top